Arcus Biosciences, Inc.
https://www.arcusbio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcus Biosciences, Inc.
Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy
Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.
Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030
At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.
Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule